37. Han X., et al. “Substantial sulfatide deficiency and ceramics elevation in very early Alzheimer’s disease: potential role in disease pathogenesis.” J Neurochem. (2002).
38. Geleijnse J., et al. “Dietary Intake of Menaquinone Is Associated with a Reduced Risk of Coronary Heart Disease: The Rotterdam Study.” J Nutr. Nov. 1, 2004.
39. “Okinawa Centenarian Study.” Jan. 26, 2018.
40. Shiraki M., et al. “Vitamin K2 (menatetrenone) Effectively Prevents Fractures and Sustains Lumbar Bone Mineral Density in Osteoporosis.” J Bone Miner Res. 2000 Mar.
41. Vermeer C., et al. “Beyond Deficiency: Potential benefits of increased intakes of vitamin K for bone and vascular health.” Eur J Nutr. 2004 Dec.
42. Feskanich D., et al. “Vitamin K intake and hip fractures in women: a prospective study.” Am J Clin Nutr. 1999 Jan.
43. Booth S., et al. “Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women.” Am J Clin Nutr. 2000 May.
44. Hauer-Jensen M. “Gods, Nuclear Weapons and Potent Pathways — How Gamma Tocotrienol Works Molecular Magic: The Mevalonate Pathway.” 05 May 2014.
45. “Toxic Chemicals Found in British Celebrities' Bodies.” EWG. May 20. 2005.
46. “Children often more contaminated than their mothers, new WWF report shows.” WWF Global. Oct. 6, 2005.
47. Haynes H. “Tocotrienols and Lipid Replacement Therapy.” May 2014.
48. Ibid.
49. Ibid.
50. “Palm Tocotrienols - Bones, Radiation, Brain Vascular Mesh.” May 2014.
51. Ibid.
52. Ibid.
53. Gopalan Y., et al. “Clinical Investigation of the Protective Effects of Palm Vitamin E Tocotrienols on brain white matter.” Stroke. 2014 May.
54. Shammas M., et al. “Telomeres, lifestyle, cancer, and aging.” Curr Opin Clin Nutr Metab Care. 2011 January.
55. Hoxha M., et al. “Association between leukocyte telomere shortening and exposure to traffic pollution: a cross-sectional study on traffic officers and indoor office workers.” Environmental Health. 2009 Sep 21.
56. Epel ES, et al., ‘Accelerated telomere shortening in response to life stress’, Proc Natl Acad Sci U S A. 2004 Dec 7; 101(49):17312-5.
57. “Palm Tocotrienols - Bones, Radiation, Brain Vascular Mesh.” May 2014.
58. Ibid.
59. Macchia A., et al. ‘Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction’, Eur J Clin Pharmacol. Jun. 2008 64(6):627-34.
60. Maki K., et al. “Krill oil supplementation increases plasma concentrations of EPA and DHA in overweight and obese men and women.” Nutr Res. 2009.
61. Mori TA, et al. Circulation. 2000; 102(11):1264-69.
62. Pharma Marine info sheet, p.1.
63. “The Influence of lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation.” Am J Clin Nutr. 2008 May.
64. Schaefer EJ, et al. Arch Neurol. 2006.
65. “Do Fish Oil Supplements Need Warning Label?” Consumer Reports.Org. March 2010.
66. Fish Oil Supplements Guide, Environmental Defense Fund, 2009.
67. Schaefer E., et al. “Plasma Phosphatidylcholine Docosahexaenoic Acid Content and Risk of Dementia and Alzheimer Disease. Arch Neurol. 2006.
68. Senftleber N., et al. “Marine Oil Supplements for Arthritic Pain: A Systematic Review and Meta-Analysis of Randomized Trials.” Nutrients. 2017.
69. SanGiovanni JP., et al. “The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS report No. 20.” Arch Ophthalmol. 2007 May.
70. Goldstein K. “Fish Oil Supplements: Is the Brand You’re Taking Safe?” Environmental Defense Fund. March 30, 2005. Press Release.
71. Deutsch L. “Krill oil reduces symptoms of chronic inflammation.” Am J Gastroenterol. 2005 Dec.